Intensive Accelerated iTBS for the Treatment-Resistant Depression
NCT: NCT06166082 · COMPLETED
Brief Summary
This study is a multicenter, randomized, double-blind, and sham-controlled trial using most intensive aiTBS protocol (10 sessions daily over 5 consecutive days at triple the standard per-session dose) to investigate the antidepressant efficacy for treatment-resistant depression (TRD). Patients will be recruited and randomly assigned (1:1 ratio) to receive active or sham groups from 5 hospitals in China. The interventions will last for 5 days and both groups will be followed up for 8 weeks on the same time schedules. During the intervention and at least the first 4 weeks of post-treatment, participants will keep a stable antidepressant regimen. The individualized target in the left dorsolateral prefrontal cortex (DLPFC) will be generated from 30 minutes of resting-state functional MRI collected at baseline.
Frequently Asked Questions
What is Intensive Accelerated iTBS for the Treatment-Resistant Depression?
Intensive Accelerated iTBS for the Treatment-Resistant Depression is a clinical trial registered under NCT06166082. Current status: COMPLETED.
What is the status of NCT06166082?
The current status of NCT06166082 (Intensive Accelerated iTBS for the Treatment-Resistant Depression) is: COMPLETED.
When did Intensive Accelerated iTBS for the Treatment-Resistant Depression start?
Intensive Accelerated iTBS for the Treatment-Resistant Depression started on 2023-12-22.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.